Long-term aspirin use not associated with risk of neovascular AMD
Long-term regular use of low-dose aspirin for 5 years does not increase the risk of neovascular age-related macular degeneration (AMD), according to a recent study, suggesting the safety of long-term use of low-dose aspirin as regards the development of neovascular AMD.
The incidence of neovascular AMD was lower among nonregular vs regular aspiring users (3.5 vs 7.2 per 10,000 person-years) in the unmatched whole cohort. However, there was no association between aspirin use and neovascular AMD in propensity score-adjusted analysis (adjusted hazard ratio [HR], 0.98; 95 percent CI, 0.73–1.30).
Propensity score-matched analyses also showed no association, with comparable incidences of neovascular AMD between nonregular and regular aspirin users (7.5 vs 7.1 per 10,000 person-years; crude HR, 0.94; 0.70–1.28). Additionally, no association was seen in a maximally adjusted model, including age, sex, income, residential area and history of 100 randomly selected types of generic drugs (adjusted HR, 0.95; 0.71–1.28).
Using a nationwide cohort from a variety of clinical and hospital in South Korea, a retrospective population-based study was conducted involving nonregular and regular aspirin users under national health insurance (aged ≥45 years) who were followed from 2010–2015.
The investigators estimated the incidence per 10,000 person-years for neovascular AMD. Long-term regular use of low-dose aspirin was defined as sustained intake of ≤100 mg aspirin with ≥1,044 days prescription between 2005 and 2009. Nonregular aspirin users included occasional users or nonusers.
Several analyses were performed, as follows: propensity score-adjusted analysis in a large, randomly selected, unmatched whole cohort (n=482,613), propensity score-matched analysis in a matched cohort (n=74,196), and maximally adjusted analysis in the unmatched whole cohort (n=482,613).